Phase I Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Patients With Advanced Solid Tumors and Phase Ib Study of CGX1321 in Combination With Pembrolizumab in Patients With Advanced Gastrointestinal Tumors
Summary
The purpose of this phase I trial is to evaluate the safety and feasibility of CGX1321 in patients with advanced solid tumors, including pancreatic adenocarcinoma.
Note: This trial is currently enrolling patients into the dose escalation part of the study.
General Information
NCT#: NCT02675946
Study ID: CGX1321-101
Trial Phase: Phase I
Trial Sponsor: Merck Sharp & Dohme Corp., Curegenix Inc.
Therapies Used in This Trial: Pembrolizumab, CGX1321